Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission.
about
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiationInsulin-like growth factor-I augments erythropoietin-induced proliferation through enhanced tyrosine phosphorylation of STAT5Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cellsMouse oncostatin M: an immediate early gene induced by multiple cytokines through the JAK-STAT5 pathwayDissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domainDifferent interleukin 2 receptor beta-chain tyrosines couple to at least two signaling pathways and synergistically mediate interleukin 2-induced proliferationA single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activityGrowth hormone promotes the association of transcription factor STAT5 with the growth hormone receptorDistinct tyrosine residues within the interleukin-2 receptor beta chain drive signal transduction specificity, redundancy, and diversityTyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15Pyk2 is a downstream mediator of the IL-2 receptor-coupled Jak signaling pathwayDifferential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activationStaphylococcal enterotoxins modulate interleukin 2 receptor expression and ligand-induced tyrosine phosphorylation of the Janus protein-tyrosine kinase 3 (Jak3) and signal transducers and activators of transcription (Stat proteins)Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation.Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.Critical role of the interleukin 2 (IL-2) receptor gamma-chain-associated Jak3 in the IL-2-induced c-fos and c-myc, but not bcl-2, gene inductionThe role of Stat5a and Stat5b in signaling by IL-2 family cytokines.The significance of tetramerization in promoter recruitment by Stat5.Stat proteins control lymphocyte proliferation by regulating p27Kip1 expression.A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5A critical role of the Thy28-MYH9 axis in B cell-specific expression of the Pax5 gene in chicken B cellsLack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.The molecular basis of IL-21-mediated proliferation.Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activationErythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activationAn IL-2 response element in the human IL-2 receptor alpha chain promoter is a composite element that binds Stat5, Elf-1, HMG-I(Y) and a GATA family protein.Requirement for an initial signal from the membrane-proximal region of the interleukin 2 receptor gamma(c) chain for Janus kinase activation leading to T cell proliferation.The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals.Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5 results in sustained DNA binding and a dominant negative phenotype.Naturally occurring dominant negative variants of Stat5.The roles for cytokines in the generation and maintenance of regulatory T cells.Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expressionDifferential requirement of the cytoplasmic subregions of gamma c chain in T cell development and function.Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.Multiple tyrosine residues in the cytosolic domain of the erythropoietin receptor promote activation of STAT5.STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line.Activation of the transcription factor ISGF3 by interferon-gamma.Biochemical analysis of interleukin-2 receptor beta chain phosphorylation by p56(lck).
P2860
Q22011170-3D91ADA6-599B-4B10-AC72-7E15FF4EA144Q24308850-88CF7719-E428-4E05-ACFA-4A9D2A51F819Q24311526-15DC7F34-72F4-4BBA-AFEC-865408594057Q24563218-3534F779-9F85-4B33-AA87-75DFE6353403Q24564909-776C04BD-2BEF-499E-9983-2CDFDFA58427Q24567993-60C7C4A4-18F3-47A4-9817-5896A2A82050Q24648750-1317565A-C754-43F4-8D85-A76A44AE6C34Q28238969-6A455E0B-5534-4FF9-BAE9-0EA7FA616F96Q28590660-017A9DDF-1932-48D8-B0E6-2849D9D60293Q28609039-09D79793-5DD8-4F94-9D51-A395E9942831Q28610814-04D52F58-860D-45F3-BAB2-385A3F406785Q28610859-EE2A4044-CA71-4923-84BA-1ABE73B91E10Q28637692-B2AF9A2F-46C7-4318-B958-F2A0DEB6D4B3Q33748769-E14E4A29-0571-43DA-900A-672E98BA5732Q33782891-70DD17DF-93E0-46EF-96AE-93380E7C627EQ33854194-A4EDE4EC-138B-4C38-8965-A29808128FDFQ33921686-9601514F-6AD0-4173-AC01-09DCB4154477Q33941389-7E7DC917-836A-44B9-94AC-143E5DDE30C4Q33957422-AB51A6FC-BA18-492F-94DB-9414FBF12EA6Q33994618-58434254-6C92-4F65-95A2-F15779681A69Q34662194-0D9E9C06-96A9-4C04-A723-CC32D8AC1FBEQ34994891-CAFF8943-C77C-4FC7-96D0-699F4B190BDDQ35745808-2B29B9A1-AAAB-443E-BFB7-EFBE8D7659E8Q35828741-013A27BA-5718-4679-ACCF-392BCFD328C4Q35850147-0B90E604-6F8A-46CA-A7D4-DFE6B5913B6EQ35906417-A40727EB-5F36-4CB1-AE6C-830B542FE2E0Q35910982-262EECC8-91A9-45B3-AF3F-44D0FA6CF4A9Q36026082-FB162807-9431-43EF-BF1F-610635D7556BQ36242620-3CC8224A-F5B3-40BE-BBD5-C840690111E8Q36558498-F1A65E7B-DB0E-45B0-8DDE-703D4AF7CC41Q36562956-49BD8C5B-68B8-48B5-A015-8E26DC09E7B7Q36563461-52557BC6-3305-42F7-AE07-49795C31266BQ36563513-2763DDC4-0C45-49F9-A325-F321D6D4ADBBQ36653664-799916C3-32D8-4897-B1EF-72766676E41BQ37250038-7AB3240B-B2EA-417E-B13D-0813C58E4472Q37387679-16BDC230-922B-4F66-826A-97B238B08616Q37400828-898EE874-9BA4-461C-8E55-B22BAB7866D1Q37625031-8027DEB3-D06B-4A30-AB18-16201BA54ACCQ38322204-0892AE94-D4BE-4409-8956-850E5616370CQ38325588-DFBF019A-F225-43CC-A849-E38DFDAB33E0
P2860
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission.
description
1995 nî lūn-bûn
@nan
1995 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Activation of Stat5 by interle ...... iferative signal transmission.
@ast
Activation of Stat5 by interle ...... iferative signal transmission.
@en
Activation of Stat5 by interle ...... iferative signal transmission.
@nl
type
label
Activation of Stat5 by interle ...... iferative signal transmission.
@ast
Activation of Stat5 by interle ...... iferative signal transmission.
@en
Activation of Stat5 by interle ...... iferative signal transmission.
@nl
prefLabel
Activation of Stat5 by interle ...... iferative signal transmission.
@ast
Activation of Stat5 by interle ...... iferative signal transmission.
@en
Activation of Stat5 by interle ...... iferative signal transmission.
@nl
P2093
P2860
P356
P1476
Activation of Stat5 by interle ...... iferative signal transmission.
@en
P2093
A Kawahara
F Gouilleux
T Miyazaki
U Schindler
Y Nakagawa
P2860
P304
P356
10.1073/PNAS.92.12.5482
P407
P577
1995-06-01T00:00:00Z